Multiple myeloma is always preceded by two precursor conditions known as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. Smoldering myeloma is associated with a higher disease burden and higher risk of progression to active disease than MGUS. The management of these precursor conditions remains unclear and the optimal timing of therapy in multiple myeloma has been a subject of debate. Whilst it would be useful to identify high-risk and asymptomatic individuals that could benefit from therapy to prevent progression to multiple myeloma, there is currently no evidence supporting the use of asymptomatic screening in clinical practice.
In this exclusive podcast recorded at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, and Sigurdur Kristinsson, MD, PhD, University of Iceland, Reykjavik, Iceland, explore the benefits and risks of screening for multiple myeloma precursor conditions, presenting the design and findings of the iStopMM (NCT03327597) and PROMISE (NCT03689595) studies. Dr Ghobrial and Prof. Kristinsson talk on emerging technologies to identify patients with myeloma precursor conditions and question the clinical significance of MGUS and smoldering myeloma, commenting on the mental impact of screening.
CAR-T therapy in myeloma and lymphoma
CAR-T therapy in AML: challenges and future outlooks
The current state of CAR-T therapy in lymphoma
Myeloma treatment updates from EHA 2022
Updates in classification and risk stratification in MDS
Myeloma 2022: day one highlights
Immune dysregulation and targeting in MDS
The future of CAR-T therapy in ALL
An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs
Key updates in the treatment and management of MPNs
Addressing unmet needs and future treatment approaches in AL amyloidosis
Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics
Updates in lymphoma and CLL treatment in the UK
The importance of early intervention and interception in myeloma
Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline
CAR-T and lymphoma treatment in the UK
Harnessing the power of immunotherapy in myeloma and amyloidosis
The impact of AI and machine learning algorithms in MDS
MMRF-CoMMpass: the genomic basis of myeloma subtypes
Genomics in the age of immuno-oncology
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.